Tenaya Therapeutics (Nasdaq: TNYA), a clinical-stage biotechnology company based in South San Francisco, has announced plans to raise approximately $52.5 million through a public offering.
The start-up said it would use the money to advance the development of its product candidates, particularly TN-201 and TN-401. Tenaya focuses on discovering, developing, and delivering therapies that address the underlying causes of heart disease.
TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, is currently in a Phase I clinical trial. TN-401, a gene therapy for a rare heart condition, is in preclinical stages.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze